GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » PS Ratio

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) PS Ratio

: 9.27 (As of Today)
View and export this data going back to 2004. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Clinuvel Pharmaceuticals's share price is $9.51. Clinuvel Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.03. Hence, Clinuvel Pharmaceuticals's PS Ratio for today is 9.27.

The historical rank and industry rank for Clinuvel Pharmaceuticals's PS Ratio or its related term are showing as below:

CLVLF' s PS Ratio Range Over the Past 10 Years
Min: 8.82   Med: 36.35   Max: 86.25
Current: 9.74

During the past 13 years, Clinuvel Pharmaceuticals's highest PS Ratio was 86.25. The lowest was 8.82. And the median was 36.35.

CLVLF's PS Ratio is ranked worse than
53.16% of 997 companies
in the Biotechnology industry
Industry Median: 8.97 vs CLVLF: 9.74

Clinuvel Pharmaceuticals's Revenue per Sharefor the six months ended in Dec. 2023 was $0.42. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.03.

Warning Sign:

Clinuvel Pharmaceuticals Ltd revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Clinuvel Pharmaceuticals was 10.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 32.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was 25.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was 46.20% per year.

During the past 13 years, Clinuvel Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 97.40% per year. The lowest was 18.80% per year. And the median was 36.80% per year.

Back to Basics: PS Ratio


Clinuvel Pharmaceuticals PS Ratio Historical Data

The historical data trend for Clinuvel Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
PS Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.72 39.71 32.69 11.70 11.83

Clinuvel Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 11.70 - 11.83 -

Competitive Comparison

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clinuvel Pharmaceuticals PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's PS Ratio falls into.



Clinuvel Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Clinuvel Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=9.51/1.026
=9.27

Clinuvel Pharmaceuticals's Share Price of today is $9.51.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clinuvel Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Clinuvel Pharmaceuticals  (OTCPK:CLVLF) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Clinuvel Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Headlines

From GuruFocus

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 07-09-2022

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 06-09-2022

US FDA sets PDUFA date for SCENESSE®

By Marketwired Marketwired 01-10-2019

3 High-Performing Stocks

By Alberto Abaterusso Alberto Abaterusso 07-12-2019

FDA Approves SCENESSE® For Genetic Disorder

By Marketwired Marketwired 10-09-2019

CLINUVEL Opens VALLAURIX R&D Centre In Singapore

By Marketwired Marketwired 08-31-2020

CLINUVEL Expands Pharmaceutical Portfolio

By Don Li2 Don Li2 11-08-2021

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 05-30-2022

CLINUVEL to Trial Innovative Drug in Stroke

By Marketwired Marketwired 10-28-2020

CLINUVEL Launches CYAC�LLE, Next Generation Solar Care

By sperokesalga sperokesalga 03-01-2023